-
公开(公告)号：US20180001013A1
公开(公告)日：2018-01-04
申请号：US15600384
申请日：2017-05-19
申请人： Brian J. Leberthon
发明人： Brian J. Leberthon
CPC分类号： A61M1/3486 , A61M1/3489 , A61M1/3493 , A61M1/3616 , A61M1/362 , A61M1/3687
摘要： A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions. Pore size is such to allow the molecular-sized activating agent in the interior of the chamber to enter the wells yet prevents immune cells and cancer cells in the wells to pass through the porous wall portions into the interior of the chamber. Blood is retained in the wells so that it remains in contact with the immune cells and cancer cells for a predetermined period sufficient to enhance an immune response. Then the cells with an enhanced immune response are return to the patient.
-
公开(公告)号：US20180001014A1
公开(公告)日：2018-01-04
申请号：US15600417
申请日：2017-05-19
申请人： Brian J. LeBerthon
发明人： Brian J. LeBerthon
CPC分类号： A61M1/36 , A61M1/3472 , A61M1/3486 , A61M1/362 , A61M1/3687
摘要： An anti-cancer substance is administered via the patient's blood ex vivo and in line by establishing a connection between the patient and a device having a chamber containing the anti-cancer substance. The patient's blood in the chamber and the anti-cancer substance interact so that immune cells in the blood (1) are activated to produce an immune response in the patient, or (2) are pre-armed by attaching to the cells antibodies, or (3) both. After activating or pre-arming the cells, the patient's treated blood is returned to the patient. The anti-cancer substance may be within the chamber prior to drawing the patient's blood into the chamber, may be introduced into the chamber after drawing the patient's blood into the chamber, or may be introduced into the chamber concurrent with the introduction of the patient's blood into the chamber. The connection is terminated after returning to the patient's blood including the activated or pre-armed cells.
-
公开(公告)号：US20160296689A1
公开(公告)日：2016-10-13
申请号：US14879019
申请日：2015-10-08
申请人： Brian J. Leberthon
发明人： Brian J. Leberthon
CPC分类号： A61M1/3486 , A61M1/3489 , A61M1/3493 , A61M1/3616 , A61M1/362 , A61M1/3687
摘要： A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions. Pore size is such to allow the molecular-sized activating agent in the interior of the chamber to enter the wells yet prevents immune cells and cancer cells in the wells to pass through the porous wall portions into the interior of the chamber. Blood is retained in the wells so that it remains in contact with the immune cells and cancer cells for a predetermined period sufficient to enhance an immune response. Then the cells with an enhanced immune response are return to the patient.
摘要翻译： 一种方法和装置治疗来自癌症患者的血液通过腔室内的通道阵列的癌症。 通道包括具有多孔膜壁部分的孔，其能够使载体流体中的分子尺寸的活化剂增强免疫应答以通过这些多孔壁部分。 孔径使得室内部的分子尺寸的活化剂进入孔中，但是防止孔中的免疫细胞和癌细胞通过多孔壁部分进入腔室的内部。 血液保留在孔中，使其保持与免疫细胞和癌细胞接触足够增强免疫应答的预定时间。 然后具有增强的免疫应答的细胞返回患者。
-
公开(公告)号：US09227005B2
公开(公告)日：2016-01-05
申请号：US13830276
申请日：2013-03-14
申请人： Brian J LeBerthon
发明人： Brian J LeBerthon
CPC分类号： A61M1/3486 , A61M1/3489 , A61M1/3493 , A61M1/3616 , A61M1/362 , A61M1/3687
摘要： A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions. Pore size is such to allow the molecular-sized activating agent in the interior of the chamber to enter the wells yet prevents immune cells and cancer cells in the wells to pass through the porous wall portions into the interior of the chamber. Blood is retained in the wells so that it remains in contact with the immune cells and cancer cells for a predetermined period sufficient to enhance an immune response. Then the cells with an enhanced immune response are return to the patient.
-
公开(公告)号：US20140303542A1
公开(公告)日：2014-10-09
申请号：US13830276
申请日：2013-03-14
申请人： Brian J. LeBerthon
发明人： Brian J. LeBerthon
IPC分类号： A61M1/36
CPC分类号： A61M1/3486 , A61M1/3489 , A61M1/3493 , A61M1/3616 , A61M1/362 , A61M1/3687
摘要： A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions. Pore size is such to allow the molecular-sized activating agent in the interior of the chamber to enter the wells yet prevents immune cells and cancer cells in the wells to pass through the porous wall portions into the interior of the chamber. Blood is retained in the wells so that it remains in contact with the immune cells and cancer cells for a predetermined period sufficient to enhance an immune response. Then the cells with an enhanced immune response are return to the patient.
摘要翻译： 一种方法和装置治疗来自癌症患者的血液通过腔室内的通道阵列的癌症。 通道包括具有多孔膜壁部分的孔，其能够使载体流体中的分子尺寸的活化剂增强免疫应答以通过这些多孔壁部分。 孔径使得室内部的分子尺寸的活化剂进入孔中，但是防止孔中的免疫细胞和癌细胞通过多孔壁部分进入腔室的内部。 血液保留在孔中，使其保持与免疫细胞和癌细胞接触足够增强免疫应答的预定时间。 然后具有增强的免疫应答的细胞返回患者。
-
公开(公告)号：US09656014B2
公开(公告)日：2017-05-23
申请号：US14879019
申请日：2015-10-08
申请人： Brian J Leberthon
发明人： Brian J Leberthon
CPC分类号： A61M1/3486 , A61M1/3489 , A61M1/3493 , A61M1/3616 , A61M1/362 , A61M1/3687
摘要： A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions. Pore size is such to allow the molecular-sized activating agent in the interior of the chamber to enter the wells yet prevents immune cells and cancer cells in the wells to pass through the porous wall portions into the interior of the chamber. Blood is retained in the wells so that it remains in contact with the immune cells and cancer cells for a predetermined period sufficient to enhance an immune response. Then the cells with an enhanced immune response are return to the patient.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.012 秒)
